

**CONFIDENTIAL MINUTES OF
MEDICAL COMMITTEE MEETING**

INSTITUTIONAL BIOSAFETY COMMITTEE

**Tuesday, 03/17/2026 12:05 PM
MSBII 5A116**

Chairperson

Mingtao Zeng, PhD

Board Members

Anthony W Baird, DSc
Jeana E. Barrow, DVM
Huanyu Dou, MD
Pallavi Dubey, PhD
Ivan E Flores, BS
Daniel Gonzales, BA

Administrative Staff

Amanda Ortiz
Myrna Arvizo

MEMBERS PRESENT
Anthony W Baird, DSc, Jeana E. Barrow, DVM, Huanyu Dou, MD, Pallavi Dubey, PhD, Ivan E Flores, BS, Mingtao Zeng, PhD, Daniel Paul Gonzales, BMS
MEMBERS ABSENT
N/A
STAFF PRESENT
Myrna Arvizo, BMS, CIP, CHRC, Amanda Diazdeleon
GUESTS PRESENT
N/A

CALL TO ORDER

Mingtao Zeng, PhD called the meeting to order at 12:05 p.m. Quorum is 5 members. 6 members are present at the call to order, including scientific, non-scientific and non-affiliated members. 7 members present at conclusion.

All proceedings and discussion in the upcoming meeting are confidential and should not be discussed outside of the meeting. Additionally, any member who has a conflict of interest that would preclude making an objective determination about a study should recuse him/herself from voting on the study.

A draft of the meeting minutes from 02/17/2026 was distributed for review on 02/20/2026. There were no controversial entries or objections. A motion to approve the meeting minutes as written was made by JB and seconded by HD. The committee voted unanimously to approve the minutes.

The meeting was adjourned at 12:35 p.m.

MISCELLANEOUS

HB 130 known as the Texas Genomic Act of 2025-The bill specifically prohibits 'Texas-based medical facilities, research institutions, companies, and nonprofits from using genome sequencing devices or related software produced by or associated with "foreign adversaries" as defined by federal law. This prohibition extends to entities domiciled in, owned by, or controlled by foreign adversaries.'

HB 130 also requires entities subject to the law to annually certify compliance to the Texas Attorney General and provides the Attorney General with investigative authority to enforce these provisions.

As a result, we will need to update the IBC application to collect information that pertains to this new bill. Information that is needed is below:

show row weights

NAME OF GENOME SEQUENCER OR SOFTWARE	NAME AND ADDRESS OF PRODUCER OF THE GENOME SEQUENCER OR SOFTWARE	COUNTRY OF ORIGIN OF THE PRODUCER OF THE GENOME SEQUENCER OR SOFTWARE	TIMEFRAME OF USAGE
		- None -	

+ -

Proposed questions and branching attached for informational purposes.

3-YEAR RENEWALS

N/A

AMENDMENTS

N/A

INITIAL REVIEWS

IBC# 26008

Full Renewal Expiration Date:

Sireesha Reddy, MD/TTUHSC El Paso - SOM - Obstetrics and Gynecology-Texas Tech Medical Center
Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:

Comment:

PI Request: Use of

Space: CSB rOOMS 209, 210, msb2 Room 4B506

Biological Agents: Human Blood, Body Fluids

Chemicals: N/A

Controlled Substances:

Biosafety Level: BSL-2

Hazardous Shipping & On-Campus Transport Training: On campus transport is required and has been assigned to Amber and Pedro

Recombinant or Synthetic Nucleic Acids: Not involved

Training Compliance: PI and all key personnel are current on required LSE, COI, and Financial Disclosure trainings

TTUHSC EP IBC Meeting Minutes - 03/17/2026

Page 1 of 2

Confidential Medical Committee: This document and all contents (including any attachments) is for the sole use of the intended recipient(s) and contains confidential or privileged information and is not to be forwarded, disclosed or otherwise given to others unless expressly authorized in writing by the TTUHSC El Paso Institutional Biosafety Committee. If you are not the intended recipient, please contact the El Paso Institutional Biosafety Committee at 915-215-4295 and destroy all documents received.

LSE training was assigned to Amber on 2/25

MEMBER COMMENTS:

Comment:

In 9.1, We will exclude patients with known HIV+ status. How about patients with HBV or HCV? In 9.2, It should list all biologics. For example, hazards for blood:

1. Bloodborne Pathogens: Hepatitis B virus (HBV), Hepatitis C virus (HCV), and Human Immunodeficiency Virus (HIV) are the most common. Other potential agents include CMV, EBV, Zika virus, and viral hemorrhagic fevers (e.g., Ebola).

2. Sharps Injuries: Needles, scalpels, broken glass, and capillary tubes contaminated with blood pose high risks.

3. Mucous Membrane/Skin Exposure: Contact of contaminated blood with eyes, mouth, or non-intact skin (e.g., rashes, dermatitis).

4. Aerosol Generation: Procedures such as centrifugation, vortexing, or pipetting can produce infectious droplets.

In 9.3, where are the spaces?

In 9.4. For example, the blood should include "1. Sharps Injuries: Contaminated needles, scalpels, or broken glass can introduce blood directly into the bloodstream. 2. Mucous Membrane Exposure: Splashes or aerosols created during centrifugation, pipetting, or vortexing can contaminate the eyes, nose, or mouth. 3. Non-intact Skin Exposure: Blood contact with dermatitis, cuts, or abrasions. 4. Ingestion: Mouth pipetting (prohibited) or contaminated hands contacting the mouth. In 9.3 The 9.5, please list the name of the biologic and the amount used in the procedure.

9.6 Please clarify the amount of biologics present in the lab

Comment:

Understood that members of the lab handling shipping/moving will have Hazardous Shipping & On-Campus Transport Training.

9.4 needs the specifics as mentioned by reviewing Dr. regarding protecting lab personnel. PPE, containment, proper storage. Concerns from Safety in line with reviewing Dr. for this protocol. No additional concerns from Safety Services/ BSO.

RECOMMENDATIONS: Additional Information Required

STIPULATIONS: 1. In 9.1, We will exclude patients with known HIV+ status. How about patients with HBV or HCV?

2. In 9.2, It should list all biologics. For example, hazards for blood: 1. Bloodborne Pathogens: Hepatitis B virus (HBV), Hepatitis C virus (HCV), and Human Immunodeficiency Virus (HIV) are the most common. Other potential agents include CMV, EBV, Zika virus, and viral hemorrhagic fevers (e.g., Ebola). 2. Sharps Injuries: Needles, scalpels, broken glass, and capillary tubes contaminated with blood pose high risks. 3. Mucous Membrane/Skin Exposure: Contact of contaminated blood with eyes, mouth, or non-intact skin (e.g., rashes, dermatitis). 4. Aerosol Generation: Procedures such as centrifugation, vortexing, or pipetting can produce infectious droplets.

3. In 9.3, where are the spaces?

4. In 9.4. For example, the blood should include "1. Sharps Injuries: Contaminated needles, scalpels, or broken glass can introduce blood directly into the bloodstream. 2. Mucous Membrane Exposure: Splashes or aerosols created during centrifugation, pipetting, or vortexing can contaminate the eyes, nose, or mouth. 3. Non-intact Skin Exposure: Blood contact with dermatitis, cuts, or abrasions.

4. Ingestion: Mouth pipetting (prohibited) or contaminated hands contacting the mouth.

Needs the specifics as mentioned by reviewing Dr. regarding protecting lab personnel. PPE, containment, proper storage.

5. 9.5, please list the name of the biologic and the amount used in the procedure.

6. 9.6 Please clarify the amount of biologics present in the lab



MOTION AND VOTE: The TTUHSC EP Institutional Biosafety Committee (IBC) reviewed the initial application at their full board meeting and determined that additional information or modifications are required. Total Members Voting: [For: 7 Absent: 0 Against: 0 Conflict of Interest: 0 Not Present: 0 Abstained: 0]

SUBMISSION OUTCOME: Additional Information Required

EXPEDITED REVIEW

IBC# 26006

Full Renewal Expiration Date: 02/28/2029

Mehri Fayazi/TTUHSC El Paso - SOD - School of Dentistry

Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:

Comment:

The PI has addressed the minor concerns of the reviewers. There will be no transport and the MSBI was removed and the MEB was added.

RECOMMENDATIONS: Acknowledged

SUBMISSION OUTCOME: Administratively Acknowledged

IBC# 26007

Full Renewal Expiration Date: 03/31/2029

Gustavo Jose Rodriguez, MD/TTUHSC El Paso - SOM - Neurology-Texas Tech Medical Center

Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:

Comment:

The PI has responded to the concerns of the reviewers. Please see the stipulation tab for reference. If no further concerns, please advise if we can approve.

MEMBER COMMENTS:

Comment:

No further concerns

RECOMMENDATIONS: Approve

SUBMISSION OUTCOME: Approved

ADMINISTRATIVE-ANNUAL STATUS REPORTS

IBC# 21009

Full Renewal Expiration Date: 03/31/2027

Ramadevi Subramani Reddy, PhD/TTUHSC El Paso - SOM - Molecular and Translational Medicine

Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:

Comment:

This is an Annual Status Report. COI, FD, and LSE are complete for the PI and staff. The study does not include shipper and on-campus training. The biosafety level is 2. This protocol does involve recombinant or synthetic nucleic acid molecules.

RECOMMENDATIONS: Acknowledged

SUBMISSION OUTCOME: Administratively Acknowledged

IBC# 18004

Full Renewal Expiration Date: 03/31/2027

Edward Michelson, MD/TTUHSC El Paso - SOM - Emergency Medicine - Texas Tech Medical Center

Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:

TTUHSC EP IBC Meeting Minutes - 03/17/2026

Page 1 of 2

Confidential Medical Committee: This document and all contents (including any attachments) is for the sole use of the intended recipient(s) and contains confidential or privileged information and is not to be forwarded, disclosed or otherwise given to others unless expressly authorized in writing by the TTUHSC El Paso Institutional Biosafety Committee. If you are not the intended recipient, please contact the El Paso Institutional Biosafety Committee at 915-215-4295 and destroy all documents received.

Comment:

This is an Annual Status Report. COI, FD, and LSE are complete for the PI and staff. The study does include shipper and on-campus training. This training is complete for those listed in section 5.5 and 5.6. The biosafety level is 2. This protocol does not involve recombinant or synthetic nucleic acid molecules.

RECOMMENDATIONS: Acknowledged

SUBMISSION OUTCOME: Administratively Acknowledged

ADMINISTRATIVE-AMENDMENTS

IBC# 21009

Full Renewal Expiration Date: 03/31/2027

Ramadevi Subramani Reddy, PhD/TTUHSC El Paso - SOM - Molecular and Translational Medicine

Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:**Comment:**

Personnel change to add Blanca Ortega. COI, FD, and LSE are complete. This protocol does involve recombinant or synthetic nucleic acid molecules.

RECOMMENDATIONS: Acknowledged

SUBMISSION OUTCOME: Administratively Acknowledged

IBC# 22008

Full Renewal Expiration Date: 09/30/2028

Subodh Kumar, PhD/TTUHSC El Paso - SOM - MTM-CoE in Infectious Diseases

Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:**Comment:**

Personnel change to add Griselda Sainz and Alexandra Marquez. COI, and LSE are complete. This protocol does involve recombinant or synthetic nucleic acid molecules.

RECOMMENDATIONS: Acknowledged

SUBMISSION OUTCOME: Administratively Acknowledged

IBC# 26004

Full Renewal Expiration Date: 10/31/2028

Hareesh Babu Bhaskaran Nair, PhD/TTUHSC El Paso - SOM - MTM-CoE in Cancer

Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:**Comment:**

Personnel change to add Shayla Hernandez. COI, FD, and LSE are complete. This protocol does involve recombinant or synthetic nucleic acid molecules.

RECOMMENDATIONS: Acknowledged

SUBMISSION OUTCOME: Administratively Acknowledged

IBC# 22008

Full Renewal Expiration Date: 09/30/2028

Subodh Kumar, PhD/TTUHSC El Paso - SOM - MTM-CoE in Infectious Diseases

Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:**Comment:**

This is a personnel change to remove Jesus Guerrero and Peter Zotor who are no longer with the working in

the lab. This protocol does involve recombinant or synthetic nucleic acid molecules.

RECOMMENDATIONS: Acknowledged

SUBMISSION OUTCOME: Administratively Acknowledged

IBC# 22010

Full Renewal Expiration Date: 08/31/2028

Umadevi Kandalam, PhD/TTUHSC El Paso - SOD - School of Dentistry

Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:

Comment:

Personnel change to add Salma Amor, Vianey Centeno, and Tanvi Patel. COI, FD, and LSE are complete. This protocol does not involve recombinant or synthetic nucleic acid molecules.

RECOMMENDATIONS: Acknowledge

SUBMISSION OUTCOME: Administratively Acknowledged

IBC# 05010

Full Renewal Expiration Date: 02/28/2029

Rajkumar Lakshmanaswamy, PhD/TTUHSC El Paso - SOM - MTM-CoE in Cancer

Biosafety Level: BSL 2

ADMINISTRATIVE COMMENT:

Comment:

Personnel change to remove Risa and Raquel.

RECOMMENDATIONS: Acknowledged

SUBMISSION OUTCOME: Administratively Acknowledged

TERMINATIONS

N/A

BSO REPORT

There were no deficiencies reported.